EP2099438A4 - Expression ex vivo et in vivo du gène thrombomoduline pour le traitement de maladies cardiovasculaires et vasculaires périphériques - Google Patents

Expression ex vivo et in vivo du gène thrombomoduline pour le traitement de maladies cardiovasculaires et vasculaires périphériques

Info

Publication number
EP2099438A4
EP2099438A4 EP07772782A EP07772782A EP2099438A4 EP 2099438 A4 EP2099438 A4 EP 2099438A4 EP 07772782 A EP07772782 A EP 07772782A EP 07772782 A EP07772782 A EP 07772782A EP 2099438 A4 EP2099438 A4 EP 2099438A4
Authority
EP
European Patent Office
Prior art keywords
vivo
cardiovascular
treatment
peripheral vascular
vascular diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07772782A
Other languages
German (de)
English (en)
Other versions
EP2099438A2 (fr
Inventor
Lakshman R Sehgal
Jonathan Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovec LLC
Original Assignee
Biovec LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/650,479 external-priority patent/US7481998B2/en
Priority claimed from US11/650,478 external-priority patent/US7501114B2/en
Priority claimed from US11/685,474 external-priority patent/US7803365B2/en
Application filed by Biovec LLC filed Critical Biovec LLC
Publication of EP2099438A2 publication Critical patent/EP2099438A2/fr
Publication of EP2099438A4 publication Critical patent/EP2099438A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/366—Thrombomodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP07772782A 2007-01-08 2007-03-14 Expression ex vivo et in vivo du gène thrombomoduline pour le traitement de maladies cardiovasculaires et vasculaires périphériques Withdrawn EP2099438A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/650,479 US7481998B2 (en) 2002-12-02 2007-01-08 Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
US11/650,478 US7501114B2 (en) 2002-12-02 2007-01-08 Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
US11/685,474 US7803365B2 (en) 2002-12-02 2007-03-13 Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
PCT/US2007/006371 WO2008088358A2 (fr) 2007-01-08 2007-03-14 Expression ex vivo et in vivo du gène thrombomoduline pour le traitement de maladies cardiovasculaires et vasculaires périphériques

Publications (2)

Publication Number Publication Date
EP2099438A2 EP2099438A2 (fr) 2009-09-16
EP2099438A4 true EP2099438A4 (fr) 2011-09-28

Family

ID=39638792

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07772782A Withdrawn EP2099438A4 (fr) 2007-01-08 2007-03-14 Expression ex vivo et in vivo du gène thrombomoduline pour le traitement de maladies cardiovasculaires et vasculaires périphériques

Country Status (3)

Country Link
EP (1) EP2099438A4 (fr)
CA (1) CA2674563C (fr)
WO (1) WO2008088358A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050844A2 (fr) * 2002-12-02 2004-06-17 Biovec Llc Expression ex vivo et in vivo du gene de thrombomoduline pour traiter des maladies cardiovasculaires et des maladies vasculaires peripheriques
US7132277B1 (en) * 2000-01-31 2006-11-07 Merck & Co., Inc. Helper dependent vector system for gene therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106124A1 (en) * 2003-02-25 2005-05-19 Sehgal Lakshman R. Therapeutic applications of thrombomodulin gene via viral and non-viral vectors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132277B1 (en) * 2000-01-31 2006-11-07 Merck & Co., Inc. Helper dependent vector system for gene therapy
WO2004050844A2 (fr) * 2002-12-02 2004-06-17 Biovec Llc Expression ex vivo et in vivo du gene de thrombomoduline pour traiter des maladies cardiovasculaires et des maladies vasculaires peripheriques

Also Published As

Publication number Publication date
WO2008088358A3 (fr) 2008-12-18
EP2099438A2 (fr) 2009-09-16
CA2674563C (fr) 2014-12-30
WO2008088358A2 (fr) 2008-07-24
CA2674563A1 (fr) 2008-07-24

Similar Documents

Publication Publication Date Title
EP1933880A4 (fr) Oligoribonucleotides et leurs methodes d'utilisation dans le traitement des maladies cardio-vasculaires
EP2155197A4 (fr) Traitement des maladies de surcharge lysosomale
SI2118074T1 (sl) Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni
PL2546253T3 (pl) Podstawione dihydropirazolony do leczenia schorzeń sercowo-naczyniowych i hematologicznych
EP2007385A4 (fr) Composition cardiovasculaire et utilisation de ladite composition pour le traitement de la maladie d'alzheimer
ZA201104011B (en) Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases
PL2034999T3 (pl) Estry DHA i ich zastosowanie w leczeniu i zapobieganiu chorobom sercowo-naczyniowym
EP2129328A4 (fr) Prothèse vasculaire et procédés d'utilisation
EP2091335A4 (fr) Utilisation de cellules hématopoïétiques cultivées ex vivo dans le traitement d'acrosyndromes
HK1203482A1 (en) Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states pde4
AU2007243282A8 (en) Compositions and methods for the treatment of cardiovascular disease
GB0608647D0 (en) Methods of diagnosis and treatment
IL211459A0 (en) Pancreatic polypeptide and variants thereof for use in the treatment of intestinal disorders
EP2220208A4 (fr) Utilisation du génotypage de l'haptoglobine dans le diagnostic et le traitement d'une maladie cardiovasculaire
SI2234631T1 (sl) Spojine in postopki za zdravljenje ĺ˝ilne bolezni
IL207247A0 (en) Use of ranolazine for the treatment of cardiovascular disease
PT2572724T (pt) Tratamento de fibroses e doenças hepáticas
IL206464A0 (en) Pharmaceutical composition, use of 2-imminopyrrolidine derivative for production of pharmaceutical composition, and kit for treatment or amelioration of heart diseases
AU2003298768A8 (en) Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
GB2442881B (en) Methods for altering gene expression and methods of treatment utilizing same
PL2307380T3 (pl) Pochodne N’-nitroksyalkilonikotynamidu do leczenia chorób układu sercowo-naczyniowego
EP2099438A4 (fr) Expression ex vivo et in vivo du gène thrombomoduline pour le traitement de maladies cardiovasculaires et vasculaires périphériques
IL191887A0 (en) Method for the diagnosis and treatment of cardiovascular diseases
HK1185345A1 (zh) 用於預防和治療心血管疾病的化合物
IL208231A0 (en) Agent for preventing and/or treating vascular diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090617

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110825

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/713 20060101ALI20110819BHEP

Ipc: A61K 31/00 20060101AFI20110819BHEP

Ipc: A61K 48/00 20060101ALI20110819BHEP

Ipc: C07H 21/00 20060101ALI20110819BHEP

17Q First examination report despatched

Effective date: 20130218

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140902

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150113